DCCC Research Center for Circulating Tumor DNA Guided Cancer Management

Steering committee

(Representatives of the participating departments and institutions)

Clinical focus areas (CFA) and National infrastructures (NI)

CFA1: Early cancer detection

Areas

Focus

National infrastructures

CFA2: Guiding adjuvant therapy decisions

CFA3: Risk stratified postoperative recurrence surveillance

CFA4: Monitoring ctDNA levels to predict therapy response

CFA5: Identi, of actionable targets and tracking of resistance causing variants

NI1: Best practice for liquid biopsy collection and pre-analytical processing

NI2: Best practice for liquid biopsy collection and pre-analytical processing

NI3: Bioinformatic procedures and algorithms for analysis & calling of ctDNA

NI4: Health economics

NI5: Education, knowledge dissemination and public awareness

Clinical Protocols (CP)

CP1 TOMBOLA Bladder DABLACA

CP2 BeTO-Ovar Ovarian DGCG

CP3 IMPROVE CRC DCCG

CP4 IMPROVE-IT CRC DCCG

CP5 IMPROVE-IT2 CRC DCCG

CP6 LUCAGEN Lung DLCG

CP7 CIMPRIL Lung DLCG

CP8 GYNctDNA Gynecological DGCG

CP9 OPTIPAL CRC DCCG

CP10 Endo III CRC DCCG

CP11 CUP CUP DMCG

CP12 CURE Upper GI DECV

CP13 Breast CDK4/6 inhibitor ctDNA Breast DBCG

CP14 Liquid Biopsies in Melanoma Melanoma DMG

CP15 PACTO Pancreas DPCG

CP16 CITHEN Head and Neck DAHANCA

CP17 MAINTAIN Bladder DABLACA

CP18 SUPE R Lung DLCG

CP19 DETECT Lung DLCG

CP20 PROMIL Lung DLCG

CP21 EndoIV CRC DCCG

CP22 ctDNAinBRAFmCRC CRC DCCG

CP23 Liver ctDNA CRC DCCG

CP24 Protarget all DMCG

CP25 CoPPO all DMCG

CP26 OC Neo Ovarian DGCG

CP27 BIOPAC Pancreas DPCG



National stakeholders, YDCCCctDNA Patients, DCS, DCCC

network

Danish hospitals and Universities

Danish multidiciplinary Cancer Groups

International advisory board

International collaborators

attached (space restriction)

CPs

CPs described in the main application text